Analyst Anthony Petrone commented, "RMD put up a $10mn/$0.02 miss; however, ex-Brightree, lower tax and onetime other gain underlying EPS declined 9% versus last year. Results were pressured by mask share losses and price erosion in the core Sleep market—risks we highlighted in our recent surveys and downgrade. Looking ahead, the new AirFit F20 mask launch will provide some offset but to what extent is unclear. Shares are still overvalued and we are lowering estimates and PT to $56."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.